Nectin Therapeutics

Nectin Therapeutics is a biotechnology company devoted to transforming the lives of cancer patients by the development of next-generation immune-oncology (IO) therapies. The company is dedicated to the development of novel therapeutic options for cancer patients. It is developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, it develops CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers. The company was established based on seminal research at the Hebrew University of Jerusalem and the University of Rijeka. Its technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody-drug-conjugates.

Nectin Therapeutics has raised $36M in total funding across 6 rounds. The company is currently at the A stage. Key investors include Guangzhou Sino-Israel Biotech Investment Fund (GIBF), Myeloma Investment Fund, Peregrine Ventures.

Nectin Therapeutics was founded in 2017 by Ofer Mandelboim (Co-founder), Pini Tsukerman (Co-founder & CSO).

Nectin Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells. Target customers: Healthcare & Life Sciences, Healthcare, Patients, Life Sciences, Pharmaceuticals.

Nectin Therapeutics is based in Givat Ram, Jerusalem, Israel, Jerusalem District. The company also has offices abroad.